Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below 200 Day Moving Average – What’s Next?

Spero Therapeutics, Inc. (NASDAQ:SPRO) shares passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.31 and traded as low as $2.27. Spero Therapeutics shares last traded at $2.27, with a volume of 195,538 shares.

Analysts Set New Price Targets

SPRO has been the subject of a number of recent analyst reports. Zacks Research lowered Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, December 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.00.

Spero Therapeutics Stock Down 1.3%

The stock has a 50-day simple moving average of $2.35 and a two-hundred day simple moving average of $2.31. The firm has a market cap of $127.89 million, a PE ratio of -2.87 and a beta of 1.48.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.12. The firm had revenue of $5.44 million during the quarter, compared to analysts’ expectations of $12.00 million. Spero Therapeutics had a negative return on equity of 125.91% and a negative net margin of 108.11%. Research analysts expect that Spero Therapeutics, Inc. will post -1.2 earnings per share for the current year.

Insider Activity

In related news, insider Esther Rajavelu sold 40,270 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $2.37, for a total transaction of $95,439.90. Following the transaction, the insider owned 869,450 shares of the company’s stock, valued at approximately $2,060,596.50. This trade represents a 4.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Spero Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. bought a new stake in Spero Therapeutics in the second quarter valued at approximately $43,000. Dimensional Fund Advisors LP bought a new position in shares of Spero Therapeutics in the third quarter worth approximately $55,000. Assenagon Asset Management S.A. purchased a new position in shares of Spero Therapeutics in the third quarter worth $70,000. Quadrature Capital Ltd bought a new stake in Spero Therapeutics during the 2nd quarter valued at $90,000. Finally, Two Sigma Investments LP purchased a new position in shares of Spero Therapeutics during the third quarter valued at about $93,000. 25.60% of the stock is owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.